Showing 201 - 218 results of 218 for search 'Regulation of genetic engineering', query time: 0.07s Refine Results
  1. 201
  2. 202
  3. 203

    Tissue-specific roles of de novo DNA methyltransferases by Dániel Márton Tóth, Flóra Szeri, Mária Ashaber, Muhyiddeen Muazu, Lóránt Székvölgyi, Tamás Arányi

    Published 2025-01-01
    “…Abstract DNA methylation, catalyzed by DNA methyltransferases (DNMT), plays pivotal role in regulating embryonic development, gene expression, adaption to environmental stress, and maintaining genome integrity. …”
    Get full text
    Article
  4. 204
  5. 205
  6. 206

    Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells by Chu-An Wang, Ya-Chin Hou, Yi-Kai Hong, Yu-Jing Tai, Chieh Shen, Pei-Chi Hou, Jhao-Lin Fu, Cheng-Lin Wu, Siao Muk Cheng, Daw-Yang Hwang, Yung-Yeh Su, Yan-Shen Shan, Shaw-Jenq Tsai

    Published 2025-01-01
    “…Methods Single-cell RNA sequencing and analysis of primary PDAC tumors were conducted. Genetically engineered pancreas-specific Kras-mutated, dual specificity phosphatase-2 (Dusp2) knockout mouse models were established. …”
    Get full text
    Article
  7. 207
  8. 208

    A novel USP4 inhibitor that suppresses colorectal cancer stemness by promoting β-catenin and Twist1 degradation by Fengtian Li, Yi Zhou, Xinyue Lin, Yaxin Zhang, Qingyong Hu, Enen Zhao, Huali Li, Xingyan Pan, Feng Shu, Kun Zhang, Chengmei Huang, Na Tang, Wenting Liao

    Published 2025-01-01
    “…Treatment with U4-I05 also inhibited tumor metastasis and extended survival in a genetically engineered CRC mouse model. Conclusions This study identifies U4-I05 as a USP4 inhibitor with significant therapeutic efficacy against CRC, offering a promising avenue for the development of new treatments targeting cancer stemness and chemotherapy resistance. …”
    Get full text
    Article
  9. 209
  10. 210
  11. 211
  12. 212
  13. 213

    <i>Ex Vivo</i> Regional Gene Therapy Compared to Recombinant BMP-2 for the Treatment of Critical-Size Bone Defects: An In Vivo Single-Cell RNA-Sequencing Study by Arijita Sarkar, Matthew C. Gallo, Jennifer A. Bell, Cory K. Mayfield, Jacob R. Ball, Mina Ayad, Elizabeth Lechtholz-Zey, Stephanie W. Chang, Osamu Sugiyama, Denis Evseenko, Jay R. Lieberman

    Published 2025-01-01
    “…<i>Ex vivo</i> regional gene therapy is a promising tissue-engineering strategy for bone regeneration: osteogenic mesenchymal stem cells (MSCs) can be genetically modified to express an osteoinductive stimulus (e.g., bone morphogenetic protein-2), seeded onto an osteoconductive scaffold, and then implanted into a bone defect to exert a therapeutic effect. …”
    Get full text
    Article
  14. 214
  15. 215
  16. 216

    PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib by Xin‐Yuan Lei, Kai‐Yue He, Qiu‐Tong Li, Lei Zhang, Dan‐Hui Wu, Jing‐Yu Yang, Jin‐Rong Guo, Meng‐Jie Liu, Zi‐Long Zhao, Jun‐Qi Li, Huai Liu, Yuan Zhao, Yu‐Jia Li, Qian‐Hui Sun, Chen‐Guang Wu, Yun‐Fan Wang, Geng‐Sheng Cao, Gang Wang, Yong‐Ping Jian, Zhi‐Xiang Xu

    Published 2024-12-01
    “…In both subcutaneous tumour models and genetically engineered mouse models of in situ esophageal cancer, HMGA1 interference increased tumour sensitivity to olaparib. …”
    Get full text
    Article
  17. 217

    Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer by Nan Niu, Keyu Li, Junke Wang, Vanessa Funes, Birginia Espinoza, Pan Li, Jianxin Wang, Melissa Lyman, Mengni He, Brian Herbst, Michael Wichroski, Ruslan Novosiadly, Sami Shoucair, Yiping Mou, Lei Zheng

    Published 2025-01-01
    “…Methods We thus tested, by using the preclinical model of PDACs including the genetically engineered mouse KPC spontaneous pancreatic tumor model and the pancreatic KPC tumor orthotopic implant model, the combinations of synthetic innate immune agonists including STING and NLRP3 agonist, respectively, and ICIs with or without chemotherapy. …”
    Get full text
    Article
  18. 218

    Incorporation of recombinant proteins into extracellular vesicles by Lactococcus cremoris by Tina Vida Plavec, Kristina Žagar Soderžnik, Giulia Della Pelle, Špela Zupančič, Robert Vidmar, Aleš Berlec

    Published 2025-01-01
    “…The presence of the most abundant lactococcal proteins in EVs fraction suggests that protein cargo-loading of EVs in L. cremoris NZ9000 is not regulated. However, our data suggests that L. cremoris NZ9000 genetically engineered to express recombinant proteins can produce EVs containing these proteins in scalable manner. …”
    Get full text
    Article